Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $310.61M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.38M
Average 1.73M
LRMR EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Larimar Therapeutics, Inc.NASDAQ: LRMR
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$29.55M, compared with -$29.19M a year earlier. Trailing-twelve-month EBITDA was -$165.68M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -105.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$29.55M+52.7% QoQ
- Last fiscal yearDec 2025
- -$165.32M-105.9% YoY
- LTMMar 2026
- -$165.68M-74.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1.2% | +100.0% | +101.2 pp |
| 1 year | -105.9% | +100.0% | +205.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (165.32M) USD
- Year-over-year change
- -105.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (165.32M) | -105.9% |
| FY2024 | 2024-12-31 | (80.29M) | -119.1% |
| FY2023 | 2023-12-31 | (36.64M) | -4.6% |
| FY2022 | 2022-12-31 | (35.04M) | +30.4% |
| FY2021 | 2021-12-31 | (50.31M) | — |
EBITDA vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -74.6% is the lowest of 11, against a peer median of -11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$5.14M USD | +92.4% | — | 2.4% | |
| LTM Mar 2026 | -CHF 64.45M CHF | -29.6% | — | 1740.8% | |
| LTM Mar 2026 | -$71.29M USD | -16.9% | — | — | |
| LTM Mar 2026 | -$78.15M USD | +14.5% | — | 2034.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$85.19M USD | +20.5% | — | — |
| LTM Mar 2026 | -$88.27M USD | +2.7% | — | 245200.0% | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$125.94M USD | -65.1% | — | — |
| LTM Mar 2026 | -$153.62M USD | -5.2% | — | — | |
| LTM Mar 2026 | -$159.48M USD | -49.1% | — | — | |
| LTM Mar 2026 | -$165.68M USD | -74.6% | — | — | |
| LTM Mar 2026 | -$193.41M USD | -17.1% | — | — | |
| Peer median (excluding LRMR) | — | -11.1% | — | 1887.4% | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.